Nationwide surveillance for Telmisartan alone or with combination at real world therapy in Indian patients with hypertension (START)

Background: Angiotensin receptor blockers (ARBs) are amongst the most preferred class of antihypertensive as reported at various evidences or guidelines. However, choice amongst ARBs differs between practicing physicians in real-life scenario. This survey aimed to understand the usage preferences of telmisartan therapy alone and in combination for treating hypertension (HT) among practitioners at various clinical settings in real-life scenario in India.Methods: A cross‑sectional survey was conducted with a pre-validated survey questionnaire consisting of 15 questions pertaining to the telmisartan and its combination usage in HT management. Total 498 registered medical practitioners (mostly physicians and cardiologists) had participated in survey. They were approached for seeking their perception, opinions, and prescribing behaviour. Categorical data was summarized by number (n) and percentage (%) in each category. Data were summarised in frequency tables.Results: Key findings from the data analysed were as follows: Around 20-40% of patients been reported to have co-morbid hypertension and diabetes as reported by majority of the physicians. Preferred class of drug in patients with hypertension with diabetes reported to be ARB. Around 90.36% of doctors reported that telmisartan was the most preferred ARB in patients with hypertension associated with high cardiovascular risk. Around 90.76% of doctors reported for their preference for telmisartan in patients with hypertension for 24-hr BP control. Around 82.93% of doctors preferred telmisartan in patients with hypertension and stroke/post-MI status.Conclusions: Indian healthcare practitioners prefer telmisartan as the most preferred ARB either alone or in a combination in patients with hypertension, including those with comorbidities

Epigenetic modulators as therapeutic targets in prostate cancer

Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management.info:eu-repo/semantics/publishedVersio

Ag(I)F as one electron oxidant for promoting sequential double desilylation : an ideal approach to non-stabilized azomethine ylides for the rapid construction of 1-azabicyclo (m:3:0) alkanes

A novel methodology for effecting sequential double desilylation by Ag(I)F for the generation of non-stabilized azomethine ylide and its application for the synthesis of 1-azabicyclo(m.3.0) alkane systems are described

Evaluation of DWT based image Fusion with three Different Resampling Methods

Abstract: The science of satellite observation is called remote sensing. In optical remote sensing, the multispectral (MS) image which contains color information is produced by three sensors covering the red, green and blue spectral wavelengths. Because of the trade-off imposed by the physical constraint between spatial and spectral resolutions, the MS image has poor spatial resolution. On the contrast, the panchromatic (PAN) images has high spatial resolution but without color information. Image fusion can combine the geometric detail of the PAN image and the color information of the MS image to produce a high-resolution MS image. -Image fusion is powerful tool to include the detail information into single image from many images taken from different sensors at different instants This study is carried out using Cartosat-2 Panchromatic image with 1m spatial resolution and Resource sat-1 Liss-IV sensor of 3 bands b 2 , b 3 and b 4 with 5.8 m spectral resolution. The images are to be pre-processed to accommodate the fusion algorithm requirements. This pre-processing may include registration and resampling of the MS and PAN images. Image Resampling is the mathematical technique used to alter the scale of an image. Popularly known basic interpolation techniques are nearest neighbor, bilinear and bicubic. These resampled MS and PAN images are fused by using Discrete Wavelet Transformations (DWT) technique. Fusion results are evaluated numerically; and quality metrix are calculated between the fused image and MS image

Stereoselective construction of X-azabicyclo[m.2.1]alkanes by [3+2]-cycloaddition of non-stabilized cyclic azomethine ylides: synthesis of enantiopure constrained amino acids and formal total synthesis of optically active epibatidine

A new and general strategy for the stereoselective construction of X-azabicyclo[m.2.1]alkanes has been developed by the [3+2]-cycloaddition of cyclic azomethine ylides with suitable achiral dipolarophiles. The cyclic azomethine ylides, where the whole of the ylide conjugation is in the ring, have been generated by the sequential double desilylation of the N-alkyl-α,α '-bis(trimethylsilyl) cyclic amines utilizing Ag(I)F as one electron oxidant. The structural rigidity of cyclic azomethine ylides has allowed preferential facial discrimination by the dipolarophile resulting into very good exo/endo selectivity. The exo/endo selectivity associated with these cycloadditions has been further exploited to access optically pure X-azabicyclo[m.2.1]alkanes by carrying out the cycloadditions with the Oppolzer's acryloyl dipolarophile. Application of this methodology is demonstrated by the construction of few constrained amino acids related to azabicyclic structural framework and the formal total synthesis of optically active epibatidine

An expeditious synthesis of epibatidine and analogues

An efficient synthesis of Epibatidine and its analogues via [3+2] cycloaddition of non-stabilised azomethine ylide and substituted 6-chloro-3-vinyl pyridine

Direct carbon-carbon bond formation strategy at a-position of tertiary amines by photoinduced electron transfer (PET) processes

Selectivity in PET reactions based on the differences in free energy (Δ Get values for radical ion formation between amines (4-7) and alllyltrimethylsilane (2) is utelized for direct allylation at a -position of 4-7 by insitu tapping of iminium cation by 2

Chemotherapy in adult soft tissue sarcoma

Soft tissue sarcomas (STSs) are rare and histologically diverse neoplasms. Recent results of various meta-analyses and development of newer drugs have changed the medical management of soft tissue sarcoma. This review gives an outline of chemotherapy and the newer targeted therapies for the same. We have carried out an extensive search in PubMed, Medline for almost all relevant articles concerning chemotherapy of soft tissue sarcoma. The available data from the literature is mainly composed of the most recent reviews, meta-analyses, phase II, and randomized phase III trials published in various peer reviewed journals and various international conferences. The role of neoadjuvant and adjuvant chemotherapy has been found to be controversial. The recent meta-analysis for adjuvant therapy in STSs has shown an increase in the overall survival with combination of ifosfamide and adriamycin. In locally advanced and metastatic STSs, single agent adriamycin remains the basic standard of medication. The combination of ifosfamide and adriamycin may also be used for rapid symptom relief and in patients planned for curative resection for metastases. Newer combinations of docetaxel and gemcitabine appear promising in selected subgroups, especially in leiomyosarcoma and malignant fibrous histiocytoma. Some recent developments include the European Union\u2032s approval of trabectedin for advanced STSs patients who had progressed on adriamycin and ifosfamide therapy. The future of mTOR inhibitors, insulin like growth factor receptor inhibitors and anti-angiogenic drugs appear quite promising. Newer methodologies such as, Bayesian adaptive randomization and inclusion of newer end points like progression-free rate, time of progression rate, and tumor growth rate will improve the results of sarcoma trials. At the end of each section we have also presented recommendations from FNx01European Society of Medical Oncology and FNx08National Comprehensive Cancer Network guidelines v.1.2009 for better correlation with the present literature